PHARMACOKINETICS AND IMMUNOGENICITY OF MAINTENANCE THERAPY WITH USTEKINUMAB: 2-YEAR RESULTS FROM THE UNIFI LONG-TERM EXTENSION STUDY

Omoniyi J. Adedokun  ¹     Remo Panaccione  ²     Tadakazu Hisamatsu  ³     Maria T. Abreu  ⁴     Rupert W.L. Leong  ⁵     David Rowbotham  ⁶     Colleen W. Marano  ⁶     Yiying Zhou  ⁶     Hongyan Zhang  ⁶     Silvio Danese  ⁷     Waqqas Afif  ⁸     Laurent Peyrin-Biroulet  ⁹     William Sandborn  ¹⁰     Bruce E. Sands  ^11    
1 Janssen Research & Development, LLC, Spring House, United States
² University of Calgary, Calgary, Canada
³ Kyorin University, Tokyo, Japan
⁴ University of Miami Miller School of Medicine, Miami, United States
⁵ Concord and Macquarie University Hospitals, Sydney, Australia
⁶ Auckland City Hospital, Auckland, New Zealand
⁷ Humanitas Research Hospital, Milan, Italy
⁸ McGill University, Montreal, Canada
⁹ Nancy University Hospital, Nancy, France
¹⁰ University of California San Diego, La Jolla, United States
¹¹ Icahn School of Medicine at Mount Sinai, New York, United States

Topic
Gut Microbiota, IBD, Immunology

Session
IBD: Drug monitoring

Conference
UEG Week Virtual 2020

Citation
United European Gastroenterology Journal 2020; 8 (Supplement 1)